U.S., July 2 -- ClinicalTrials.gov registry received information related to the study (NCT07679061) titled 'First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)' on June 25.
Brief Summary: This study looks at how a combination of two medicines, nivolumab and ipilimumab, is used to treat people with advanced liver cancer that cannot be removed by surgery. The study will follow adults receiving this treatment in routine medical care in Japan to understand how safe it is, how well it works, and how it is used in standard clinical practice.
Study Start Date: March 05
Study Type: OBSERVATIONAL
Condition:
Unresectable Hepatocellular Carcinoma
Intervention:
COMBINATION_PRODUCT: Nivolumab plus ipilimumab...